Tocilizumab or glucocorticoids treatment for patients with SARS-CoV-2 pneumonia: An observational study.

ABSTRACT:

Objective

To estimate the effect of tocilizumab or glucocorticoids in preventing death and intubation in patients hospitalized with SARS-CoV-2 pneumonia.

Methods

This was a retrospective cohort study enrolling all consecutive patients hospitalized at Reggio Emilia AUSL between February the 11^th and April 14^th 2020 for severe COVID-19 and treated with tocilizumab or glucocorticoids (at least 80 mg/day of methylprednisolone or equivalent for at least 3 days). The primary outcome was death within 30 days from the start of the considered therapies. The secondary outcome was a composite outcome of death and/or intubation. All patients have been followed-up until May 19^th 2020, with a follow-up of at least 30 days for every patient. To reduce confo

SUBMITTER: Dolci G 

PROVIDER: S-EPMC8687752 | biostudies-literature | 2022 Jan-Feb

REPOSITORIES: biostudies-literature